المؤلفون: V.M. Unguryan, A.N. Kazantsev, A.V. Korotkikh, S.A. Ivanov, Yu.V. Belov, A.D. Kaprin

المصدر: Патология кровообращения и кардиохирургия, Vol 27, Iss 3, Pp 74-82 (2023)

مصطلحات موضوعية: изолированная химиоперфузия печени, метастазы в печени, метастазы увеальной меланомы, увеальная меланома, Surgery, RD1-811

وصف الملف: electronic resource

Relation: https://journalmeshalkin.ru/index.php/heartjournal/article/view/1226; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

URL الوصول: https://doaj.org/article/58e167deabbb46a6824640e7d54611e8

المؤلفون: S. F. Evdokimova, L. V. Bolotina, A. L. Kornietskaya, D. V. Sidorov, A. D. Kaprin, С. Ф. Евдокимова, Л. В. Болотина, А. Л. Корниецкая, Д. В. Сидоров, А. Д. Каприн

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 154-160 ; Медицинский Совет; № 22 (2023); 154-160 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: выживаемость без признаков болезни, metachronous metastases, adjuvant chemotherapy, radical resection, disease-free interval, unfavorable prognostic factors, liver metastases, disease-free survival, метахронные метастазы, адъювантная химиотерапия, радикальная резекция, безрецидивный интервал, факторы неблагоприятного прогноза, метастазы в печень

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8001/7090; Osterlund P, Salminen T, Soveri LM, Kallio R, Kellokumpu I, Lamminmäki A et al. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur. 2021;3:100049. https://doi.org/10.1016/j.lanepe.2021.100049.; Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2710–2718. https://doi.org/10.1158/1055-9965.EPI-20-0490.; Duineveld LA, van Asselt KM, Bemelman WA, Smits AB, Tanis PJ, van Weert HC, Wind J. Symptomatic and Asymptomatic Colon Cancer Recurrence: A Multicenter Cohort Study. Ann Fam Med. 2016;14(3):215–220. https://doi.org/10.1370/afm.1919.; Haria PD, Baheti AD, Palsetia D, Ankathi SK, Choudhari A, Guha A et al. Follow-up of colorectal cancer and patterns of recurrence. Clin Radiol. 2021;76(12):908–915. https://doi.org/10.1016/j.crad.2021.07.016.; Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–1215. https://doi.org/10.1016/S1470-2045(13)70447-9.; Araujo RL, Gönen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(9):3070–3078. https://doi.org/10.1245/s10434-014-4354-6.; Kobayashi S, Beppu T, Honda G, Yamamoto M, Takahashi K, Endo I et al. Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases-a Japanese Nationwide Survey. J Gastrointest Surg. 2020;24(6):1244–1260. https://doi.org/10.1007/s11605-019-04250-9.; Wang ZM, Chen YY, Chen FF, Wang SY, Xiong B. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: A meta-analysis. Eur J Surg Oncol. 2015;41(9):1197–1203. https://doi.org/10.1016/j.ejso.2015.05.020.; Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 2012;27(6):1849–1856. https://doi.org/10.3892/or.2012.1740.; Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26(30):4906–4911. https://doi.org/10.1200/JCO.2008.17.3781.; Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24(31):4976–4982. https://doi.org/10.1200/JCO.2006.06.8353.; Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20(4):674–680. https://doi.org/10.1093/annonc/mdn680.; Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78. https://doi.org/10.1186/s12885-017-3925-x.; Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z et al. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). J Hematol Oncol. 2019;12(1):16. https://doi.org/10.1186/s13045-019-0702-0.; Lumachi F, Chiara GB, Tozzoli R, Del Conte A, Basso SM. Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis. Anticancer Res. 2016;36(1):13–19. https://ar.iiarjournals.org/content/36/1/13.long.; Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am. 2002;82(5):1075–1090. https://doi.org/10.1016/s0039-6109(02)00051-8.; Liu LL, Sun JD, Xiang ZL. Survival nomograms for colorectal carcinoma patients with lung metastasis and lung-only metastasis, based on the SEER database and a single-center external validation cohort. BMC Gastroenterol. 2022;22(1):446. https://doi.org/10.1186/s12876-022-02547-9.; Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J, Koch M. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer. 2014;14:174. https://doi.org/10.1186/1471-2407-14-174.; Федянин МЮ, Гладков ОА, Гордеев СС, Карачун АМ, Козлов НА, Мамедли ЗЗ и др. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли. 2022;12(3s2–1):401–454. https://doi.org/10.18027/2224-5057-2022-12-3s2-401-454.; Kanemitsu Y, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D et al. Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial. J Clin Oncol. 2021;39(34):3789–3799. https://doi.org/10.1200/JCO.21.01032.; Mauri D, Zarkavelis G, Filis P, Tsali L, Zafeiri G, Papadaki A et al. Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials. ESMO Open. 2018;3(4):e000343. https://doi.org/10.1136/esmoopen-2018-000343.; Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG et al. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol. 2016;22(2):519–533. https://doi.org/10.3748/wjg.v22.i2.519.; Park HS, Jung M, Shin SJ, Heo SJ, Kim CG, Lee MG et al. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. Ann Surg Oncol. 2016;23(3):928–935. https://doi.org/10.1245/ s10434-015-4951-z.; Zhang C, Tan Y, Xu H. Does adjuvant chemotherapy improve the prognosis of patients after resection of pulmonary metastasis from colorectal cancer? A systematic review and meta-analysis. Int J Colorectal Dis. 2019;34(10):1661–1671. https://doi.org/10.1007/s00384-019-03362-7.; Imanishi M, Yamamoto Y, Hamano Y, Yamada T, Moriwaki T, Gosho M et al. Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. Eur J Cancer. 2019;106:69–77. https://doi.org/10.1016/j.ejca.2018.10.003.; https://www.med-sovet.pro/jour/article/view/8001

الاتاحة: https://www.med-sovet.pro/jour/article/view/8001
https://doi.org/10.21518/ms2023-453

المؤلفون: M. I. Sokolova, V. I. Pavlova, М. И. Соколова, В. И. Павлова

المصدر: Creative surgery and oncology; Том 14, № 3 (2024); 216-222 ; Креативная хирургия и онкология; Том 14, № 3 (2024); 216-222 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: иммуногистохимия, neoplasm metastasis, neck lymph nodes, P­16 expression, PD­L1, squamous cell carcinoma, chemotherapy, radiotherapy, tonsillectomy, immunohistochemistry, новообразований метастазы, шейные лимфатические узлы, экспрессия Р­16, плоскоклеточный рак, химиотерапия, лучевая терапия, тонзиллэктомия

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/982/612; Frost P. Unknown primary tumors: an example of accelerated (type 2) tumor progression. Basic Life Sci. 1991;57:233–7; discussion 237–40. DOI:10.1007/978-1-4684-5994-4_20; Varadhachary G. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin Cancer Res. 2013;19:4027–33. DOI:10.1158/1078-0432.CCR-12-3030; Куликов Е.П., Захаркина Т.В., Сашина Е.Л., Мануковская О.В., Редькин А.Н., Чевардов Н.И. и др. Поиск первичного очага при метастатическом поражении лимфоузлов шеи. Российский медико-биологический вестник им. академика И.П. Павлова. 2016;24(4):119–25. DOI:10.23888/PAVLOVJ20164119-125; Al Kadah B., Papaspyrou G., Linxweiler M., Schick B, Rübe C., Büchler B.S., et al. Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 patients. Eur Arch Otorhinolaryngol. 2017;274:2557–66. DOI:10.1007/s00405-017-4525-8; Рудык А.Н., Зинченко С.В., Хасанов Р.Ш., Хамидуллин Р.Г., Чернышева В.А. Определение локализации первичной опухоли у пациентов с метастазами в лимфатические узлы шеи без выявленного первичного очага. Онкохирургия. 2013;5(2):57–9.; Саприна О.А. Метастазы плоскоклеточного рака в лимфоузлы шеи без выявленного первичного очага. Опухоли головы и шеи. 2012;4:53–8. DOI:10.17650/2222-1468-2012-0-4-53-58; Farooq S., Khandavilli S., Dretzke J., Moore D., Nankivell P.C., Sharma N., et al. Transoral tongue base mucosectomy for the identification of the primary site in the work-up of cancers of unknown origin: Systematic review and meta-analysis. Oral Oncol. 2019;91:97–106. DOI:10.1016/j.oraloncology.2019.02.018; Mistry R., Walker A., Kim D., Ofo E. Transoral robotic surgery for the benefit of patients with head and neck cancer of unknown primary: our experience at St George’s University Hospital, London. Ann R Coll Surg Engl. 2020;102(6):442–50. DOI:10.1308/rc-sann.2020.0071; Al-Lami A., Gao C., Saddiq M., Al Zuhir N., Simo R., Arora A., et al. Reducing the unknowns: A systematic review & meta-analysis of the effectiveness of trans-oral surgical techniques in identifying head and neck primary cancer in carcinoma unknown primary. Oral Oncol. 2022;126:105–7. DOI:10.1016/j.oraloncology; Kubik M.W., Channir H.I., Rubek N., Kim S., Ferris R.L., von Buchwald C., et al. TORS Base-of-Tongue mucosectomy in human papilloma virus-negative carcinoma of unknown primary. Laryngoscope. 2021;131(1):78–81. DOI:10.1002/lary.28617; Liu X., Li D., Li N., Zhu X. Optimization of radiotherapy for neck carcinoma metastasis from unknown primary sites: a meta-analysis. Oncotarget. 2016;7(48):78736–46. DOI:10.18632/oncotarget.12852; Maghami E., Ismaila N., Alvarez A., Chernock R., Duvvuri U., Geiger J., et al. Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO Guideline. J Clin Oncol. 2020;38(22):2570–96. DOI:10.1200/JCO.20.00275; Chen A.M., Farwell D.G., Lau D.H., Li B.Q., Luu Q., Donald P.J. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio? Int J Radiat Oncol Biol Phys. 2011;81(2):346–52. DOI:10.1016/j.ijrobp.2010.06.031; Ofo E., Spears H., Kim D., Duvvuri U. Transoral robotic surgery and unknown primary surgery. ORL J Otorhinolaryngol Relat Spec. 2018;80:148–55. DOI:10.1159/000490596; Civantos F.J., Vermorken J.B., Shah J.P., Rinaldo A., Suárez C., Kowalski L.P., et al. Metastatic squamous cell carcinoma to the cervical lymph nodes from an unknown primary cancer: management in the HPV era. Front Oncol. 2020;10:593164. DOI:10.3389/fonc.2020.593164; https://www.surgonco.ru/jour/article/view/982

الاتاحة: https://www.surgonco.ru/jour/article/view/982
https://doi.org/10.24060/2076-3093-2024-14-3-216-222

المؤلفون: Marga, S., Mereuţă, I.E., Мереуцэ, И.Е., Şveţ, V.

المصدر: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 78 (1) 253-255

مصطلحات موضوعية: DWI-BS în regim corp integru, TC, Scintigrafia osoasă, tumoare malignă, metastaze, produsenutraceutice, nanoparticule, produse liposomale, Whole body DWI-BS, CT, Bone scintigraphy, malignant tumor, metastases, nutraceutical products, nanoparticles, liposomal products, DWI-BS всего тела, КТ, сцинтиграфия костей, злокачественная опухоль, метастазы, нутрицевтики, наночасти цы, липосомальные продукты

وصف الملف: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/210038; urn:issn:18570011

الاتاحة: https://ibn.idsi.md/vizualizare_articol/210038
https://doi.org/10.52692/1857-0011.2024.1-78.31

المؤلفون: Bakholdina, Y. S., Timeeva, L. V., Samoylova, T. P., Бахолдина, Я. С., Тимеева, Л. В., Самойлова, Т. П.

المصدر: Сборник статей

مصطلحات موضوعية: CERVICAL CANCER, HUMAN PAPILLOMAVIRUS (HPV), CERVICAL CANAL, METASTASES, TUMOR, РАК ШЕЙКИ МАТКИ, ВИРУС ПАПИЛЛОМЫ ЧЕЛОВЕКА (ВПЧ), ЦЕРВИКАЛЬНЫЙ КАНАЛ, МЕТАСТАЗЫ, ОПУХОЛЬ

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения : Сборник статей IX Международной научно-практической конференции молодых ученых и студентов, 17-18 апреля 2024 г. Т. 1.; Бахолдина, Я. С. Карцинома шейки матки / Я. С. Бахолдина, Л. В. Тимеева, Т. П. Самойлова. - Текст: электронный // Актуальные вопросы современной медицинской науки и здравоохранения : Сборник статей IX Международной научно-практической конференции молодых ученых и студентов, 17-18 апреля 2024 г. Т. 1. - Екатеринбург, 2024. – C. 593-596.; http://elib.usma.ru/handle/usma/21308

الاتاحة: http://elib.usma.ru/handle/usma/21308

المؤلفون: D. V. Semyonov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, N. A. Karlova, Д. В. Семенов, Р. В. Орлова, В. И. Широкорад, С. В. Кострицкий, Н. А. Карлова

المصدر: Siberian journal of oncology; Том 23, № 2 (2024); 37-46 ; Сибирский онкологический журнал; Том 23, № 2 (2024); 37-46 ; 2312-3168 ; 1814-4861

مصطلحات موضوعية: прогностические факторы, lung metastases, overall survival, prognostic factors, метастазы в легкие, общая выживаемость

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3037/1215; Hua K.C., Hu Y.C. Establishment of predictive model for patients with kidney cancer bone metastasis: a study based on SEER database. Transl Androl Urol. 2020; 9(2): 523–43. https://doi.org/10.21037/tau.2020.01.24.; Ged Y., Voss M.H. Novel emerging biomarkers to immunotherapy in kidney cancer. Ther Adv Med Oncol. 2021; 13. doi:10.1177/17588359211059367.; Chung C. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer. Am J Health Syst Pharm. 2020; 77(24): 2064–73. doi:10.1093/ajhp/zxaa308.; Xue J., Chen W., Xu W., Xu Z., Li X., Qi F., Wang Z. Patterns of distant metastases in patients with clear cell renal cell carcinoma A population-based analysis. Cancer Med. 2021; 10(1): 173–87. doi:10.1002/cam4.3596.; Nishida J., Momoi Y., Miyakuni K., Tamura Y., Takahashi K., Koinuma D., Miyazono K., Ehata S. Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nat Cell Biol. 2020; 22(4): 465–75. doi:10.1038/s41556-020-0491-2.; Zhang G., Zhang L., Sun S., Chen M. Identification of a Novel Defined Immune-Autophagy-Related Gene Signature Associated With Clinical and Prognostic Features of Kidney Renal Clear Cell Carcinoma. Front Mol Biosci. 2021; 8. doi:10.3389/fmolb.2021.790804.; Abdel-Rahman O. Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncol. 2017; 13(22): 1967–80. doi:10.2217/fon-2017-0175.; Lin S., Zheng Y., Qin Z., Hu X., Qi F., Yin R., Xu L., Li X. Surgical intervention in renal cell carcinoma patients with lung and bronchus metastasis is associated with longer survival time: a population-based analysis. Ann Transl Med. 2019; 7(14): 323. doi:10.21037/atm.2019.06.02.; Danno T., Iwata S., Niimi F., Honda S., Okada H., Azuma T. Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma. Case Rep Urol. 2021. doi:10.1155/2021/9936330.; Schulz S., Woerl A.C., Jungmann F., Glasner C., Stenzel P., Strobl S., Fernandez A., Wagner D.C., Haferkamp A., Mildenberger P., Roth W., Foersch S. Multimodal Deep Learning for Prognosis Prediction in Renal Cancer. Front Oncol. 2021; 11. doi:10.3389/fonc.2021.788740.; Xi W., Hou Y., Hu X., Xia Y., Jiang S., Wang H., Bai Q., Hou J., Guo J. Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Transl Androl Urol. 2021; 10(11): 4132–41. doi:10.21037/tau-21-429.; Xu C., Zhou Q., Liu W., Li W., Dong S., Li W., Xu X., Qiao X., Jiang Y., Chen J., Yin C. Dynamic Predictive Models with Visualized Machine Learning for Assessing the Risk of Lung Metastasis in Kidney Cancer Patients. J Oncol. 2022. doi:10.1155/2022/5798602.; Xiao R., Liu C., He W., Ma L. Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma. Biomed Res Int. 2021. doi:10.1155/2021/6736008.; Volpe A., Bollito E., Bozzola C., Di Domenico A., Bertolo R., Zegna L., Duregon E., Boldorini R., Porpiglia F., Terrone C. Classification of Histologic Patterns of Pseudocapsular Invasion in Organ-Confined Renal Cell Carcinoma. Clin Genitourin Cancer. 2016; 14(1): 69–75. doi:10.1016/j.clgc.2015.07.020.; Bridgeman V.L., Vermeulen P.B., Foo S., Bilecz A., Daley F., Kostaras E., Nathan M.R., Wan E., Frentzas S., Schweiger T., Hegedus B., Hoetzenecker K., Renyi-Vamos F., Kuczynski E.A., Vasudev N.S., Larkin J., Gore M., Dvorak H.F., Paku S., Kerbel R.S., Dome B., Reynolds A.R. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol. 2017; 241(3): 362–74. doi:10.1002/path.4845.; Lu Z., Yang C., He W., Zhou J., Xiang R. Nomogram to predict risk and prognosis of synchronous lung metastasis in renal cell carcinoma: A large cohort analysis. Medicine (Baltimore). 2022; 101(27). doi:10.1097/MD.0000000000029764.; Petrozza V., Costantini M., Tito C., Giammusso L.M., Sorrentino V., Cacciotti J., Porta N., Iaiza A., Pastore A.L., Di Carlo A., Simone G., Carbone A., Gallucci M., Fazi F. Emerging role of secreted miR-210-3p as potential biomarker for clear cell Renal Cell Carcinoma metastasis. Cancer Biomark. 2020; 27(2): 181–8. doi:10.3233/CBM-190242.; https://www.siboncoj.ru/jour/article/view/3037

الاتاحة: https://www.siboncoj.ru/jour/article/view/3037
https://doi.org/10.21294/1814-4861-2024-23-2-37-46

المؤلفون: A. Yu. Dobrodeev, D. N. Kostromitsky, A. S. Tarasova, S. G. Afanasyev, N. N. Babyshkina, A. A. Ponomaryeva, I. V. Larionova, T. A. Dronova, D. I. Azovsky, А. Ю. Добродеев, Д. Н. Костромицкий, А. С. Тарасова, С. Г. Афанасьев, Н. Н. Бабышкина, А. А. Пономарева, И. В. Ларионова, Т. А. Дронова, Д. И. Азовский

المساهمون: The study was supported by the Russian Science Foundation grant No. 22-15-00212 dated May 13, 2022 “Transcriptomic and proteomic markers for the prognosis and effectiveness of therapy for metastatic colon cancer.”, Работа поддержана грантом РНФ № 22-15-00212 от 13.05.2022 «Транскриптомные и протеомные маркеры прогноза и эффективности терапии метастатического рака толстой кишки».

المصدر: Siberian journal of oncology; Том 23, № 1 (2024); 162-169 ; Сибирский онкологический журнал; Том 23, № 1 (2024); 162-169 ; 2312-3168 ; 1814-4861

مصطلحات موضوعية: полная регрессия, liver metastases, preoperative chemotherapy, targeted therapy, complete regression, метастазы в печень, предоперационная химиотерапия, таргетная терапия

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2969/1207; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi:10.3322/caac.21660.; Engstrand J., Strömberg C., Nilsson H., Freedman J., Jonas E. Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition. World J Surg Oncol. 2019; 17(1): 228. doi:10.1186/s12957-019-1771-9.; Calderon Novoa F., Ardiles V., de Santibañes E., Pekolj J., Goransky J., Mazza O., Sánchez Claria R., de Santibañes M. Pushing the Limits of Surgical Resection in Colorectal Liver Metastasis: How Far Can We Go? Cancers (Basel). 2023; 15(7): 2113. doi:10.3390/cancers15072113.; Mohamad I., Barry A., Dawson L., Hosni A. Stereotactic body radiation therapy for colorectal liver metastases. Int J Hyperthermia. 2022; 39(1): 611–9. doi:10.1080/02656736.2021.1923836.; Афанасьев С.Г., Тузиков С.А. Нерезектабельные опухоли печени (обзор литературы). Сибирский онкологический журнал. 2006; 1: 49–54.; de Jong M.C., Pulitano C., Ribero D., Strub J., Mentha G., Schulick R.D., Choti M.A., Aldrighetti L., Capussotti L., Pawlik T.M. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009; 250(3): 440–8. doi:10.1097/SLA.0b013e3181b4539b.; Tournigand C., André T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229–37. doi:10.1200/JCO.2004.05.113. Corrected and republished in: J Clin Oncol. 2023; 41(19): 3469–77.; Benoist S., Brouquet A., Penna C., Julié C., El Hajjam M., Chagnon S., Mitry E., Rougier P., Nordlinger B. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006; 24(24): 3939–45. doi:10.1200/JCO.2006.05.8727.; Добродеев А.Ю., Костромицкий Д.Н., Тарасова А.С., Афанасьев С.Г., Бабышкина Н.Н., Пономарева А.А., Ермоленко Р.В., Фролова И.Г., Черемисина О.В. Непосредственные результаты неоадъювантной химиотерапии у больных метастатическим колоректальным раком с изолированным поражением печени. Сибирский онкологический журнал. 2022; 21(6): 17–24. doi.:10.21294/1814-4861-2022-21-6-17-24.; Chow F.C., Chok K.S. Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol. 2019; 11(2): 150–72. doi:10.4254/wjh.v11.i2.150.; Ardito F., Panettieri E., Vellone M., Ferrucci M., Coppola A., Silvestrini N., Arena V., Adducci E., Capelli G., Vecchio F.M., Giovannini I., Nuzzo G., Giuliante F. The impact of R1 resection for colorectal liver metastases on local recurrence and overall survival in the era of modern chemotherapy: An analysis of 1,428 resection areas. Surgery. 2019; 165(4): 712–20. doi:10.1016/j.surg.2018.09.005.; Falcone A., Ricci S., Brunetti I., Pfanner E., Allegrini G., Barbara C., Crinò L., Benedetti G., Evangelista W., Fanchini L., Cortesi E., Picone V., Vitello S., Chiara S., Granetto C., Porcile G., Fioretto L., Orlandini C., Andreuccetti M., Masi G.; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25(13): 1670–6. doi:10.1200/JCO.2006.09.0928.; Martin J., Petrillo A., Smyth E.C., Shaida N., Khwaja S., Cheow H.K., Duckworth A., Heister P., Praseedom R., Jah A., Balakrishnan A., Harper S., Liau S., Kosmoliaptsis V., Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol. 2020; 11(10): 761–808. doi:10.5306/wjco.v11.i10.761.; Araujo R.L.C., Milani J.M., Armentano D.P., Moreira R.B., Pinto G.S.F., de Castro L.A., Lucchesi F.R. Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy. J Surg Oncol. 2020; 121(5): 848–56. doi:10.1002/jso.25784.; Xu D., Yan X.L., Liu J.M., Li J., Xing B.C. The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy. J Cancer. 2020; 11(21): 6256–63. doi:10.7150/jca.47911.; Adam R., Wicherts D.A., de Haas R.J., Aloia T., Lévi F., Paule B., Guettier C., Kunstlinger F., Delvart V., Azoulay D., Castaing D. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008; 26(10): 1635–41. doi:10.1200/JCO.2007.13.7471.; Barimani D., Kauppila J.H., Sturesson C., Sparrelid E. Imaging in disappearing colorectal liver metastases and their accuracy: a systematic review. World J Surg Onc. 2020; 18. doi:10.1186/s12957-020-02037-w.; https://www.siboncoj.ru/jour/article/view/2969

الاتاحة: https://www.siboncoj.ru/jour/article/view/2969
https://doi.org/10.21294/1814-4861-2024-23-1-162-169

المؤلفون: A. I. Babich, M. A. Privalov, A. E. Demko, V. A. Reva, V. A. Manukovskiy, V. V. Cheremisov, I. V. Reshetov, А. И. Бабич, М. А. Привалов, А. Е. Демко, В. A. Рева, В. А. Мануковский, В. В. Черемисов, И. В. Решетов

المصدر: Siberian journal of oncology; Том 23, № 1 (2024); 155-161 ; Сибирский онкологический журнал; Том 23, № 1 (2024); 155-161 ; 2312-3168 ; 1814-4861

مصطلحات موضوعية: метастазы колоректального рака, liver metastases, colorectal cancer metastases, метастатическое поражение печени

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2968/1206; Поликарпов А.А., Таразов П.Г., Гранов Д.А., Полысалов В.Н. Рентгенэндоваскулярные процедуры в лечении больных с нерезектабельными метастазами колоректального рака в печени. Российский онкологический журнал. 2014; 19(4): 40–1.; Adam R., Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019; 3(1): 50–6. doi:10.1002/ags3.12227.; Tzeng C., Aloia T. Colorectal Liver Metastases. J Gastrointest Surg. 2012; 17: 195–201. doi:10.1007/s11605-012-2022-3.; Gruber-Rouh T., Naguib N., Eichler K., Ackermann H., Zangos S., Trojan J., Beeres M., Harth M., Schulz B., Nour-Eldin A., Vogl T.J. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int J Cancer. 2013; 134: 1225–31. doi:10.1002/ijc.28443.; Alexander H.R., Bartlett D.L., Libutti S.K., Pingpank J.F., Fraker D.L., Royal R., Steinberg S.M., Helsabeck C.B., Beresneva T.H. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009; 16(7): 1852–9. doi:10.1245/s10434-009-0482-9.; Ben-Shabat I., Hansson C.,Eilard M., Cahlin C., Rizell M., Lindnér P., Mattsson J., Bagge R. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. J Vis Exp. 2015; (95): 52490. doi:10.3791/52490.; van Iersel L.B.J., Koopman M., van de Velde C.J.H., Mol L., van Persijn van Meerten E.L., Hartgrink H.H., Kuppen P.J.K., Vahrmeijer A.L., Nortier J.W.R., Tollenaar R.A.E.M., Punt C., Gelderblom H. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol. 2010; 21(8): 1662–7. doi:10.1093/annonc/mdp589.; Hafström L.R., Holmberg S.B., Naredi P.L., Lindnér P.G., Bengtsson A., Tidebrant G., Scherstén T.S. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994; 3(2): 103–8. doi:10.1016/0960-7404(94)90005-1.; Huibers A., DePalo D.K., Perez M.C., Zager J.S., Olofsson Bagge R. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. Clin Exp Metastasis. 2023. doi:10.1007/s10585-023-10234-6.; Olofsson Bagge R., Nelson A., Shafazand A., All-Eriksson C., Cahlin C., Elander N., Helgadottir H., Kiilgaard J.F., Kinhult S., Ljuslinder I., Mattsson J., Rizell M., Sternby Eilard M., Ullenhag G.J., Nilsson J.A., Ny L., Lindnér P. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). J Clin Oncol. 2023; 41(16): 3042–50. doi:10.1200/JCO.22.01705.; Bethlehem M.S., Katsarelias D., Olofsson Bagge R. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. Cancers (Basel). 2021; 13(18): 4726. doi:10.3390/cancers13184726.; Eggermont A.M., van IJken M.G., van Etten B., van der Sijp J.R., ten Hagen T.L., Wiggers T., Oudkerk M., de Boeck G., de Bruijn E.A. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology. 2000; 47(33): 776–81.; Dewald C.L.A., Becker L.S., Maschke S.K., Meine T.C., Alten T.A., Kirstein M.M., Vogel A., Wacker F.K., Meyer B.C., Hinrichs J.B. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis. 2020; 37(6): 683–92. doi:10.1007/s10585-020-10057-9.; Vogel A., Ochsenreither S., Zager J.S., Wacker F., Saborowski A. Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. Cancer Treat Rev. 2023; 113: 102501. doi:10.1016/j.ctrv.2022.102501.; Rowcroft A., Loveday B.P.T., Thomson B.N.J., Banting S., Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020; 22(4): 497–505. doi:10.1016/j.hpb.2019.11.002.; https://www.siboncoj.ru/jour/article/view/2968

الاتاحة: https://www.siboncoj.ru/jour/article/view/2968
https://doi.org/10.21294/1814-4861-2024-23-1-155-161

المؤلفون: A. I. Autenshlyus, S. A. Arkhipov, E. S. Mikhaylova, V. V. Arkhipova, N. A. Varaksin, А. И. Аутеншлюс, С. А. Архипов, Е. С. Михайлова, В. В. Архипова, Н. А. Вараксин

المساهمون: The study was funded within the framework of the state task (no. AAAAA-A18-118030790008-7) of the Ministry of Health of the Russian Federation., Исследование профинансировано в рамках государственного задания (№ АААА-А18-118030790008-7) Министерства здравоохранения Российской Федерации.

المصدر: Siberian journal of oncology; Том 22, № 6 (2023); 92-102 ; Сибирский онкологический журнал; Том 22, № 6 (2023); 92-102 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-0-31-36

مصطلحات موضوعية: метастазы в региональные лимфатические узлы, histopathological parameters, markers of molecular subtypes, CD34, cytokines, metastases to regional lymph nodes, гистопатологические параметры, маркеры молекулярных подтипов, цитокины

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2839/1184; Korkaya H., Orsulic S. Editorial: The tumor microenvironment: Recent advances and novel therapeutic approaches. Front Cell Dev Biol. 2020; 8. doi:10.3389/fcell.2020.586176.; Esquivel-Velazquez M.E., Ostoa-Saloma P., Palacios-Arreola M.I., Nava-Castro K.E., Castro J.I., Montor J.M. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015; 35(1): 1–16. doi:10.1089/jir.2014.0026.; Panis C., Pavanelli W.R. Cytokines as mediators of painrelated process in breast cancer. Mediators Inflamm. 2015. doi:10.1155/2015/129034.; Paccagnella M., Abbona A., Michelotti A., Geuna E., Ruatta F., Landucci E., Denaro N., Vanella P., Lo Nigro C., Galizia D., Merlano M., Garrone O. Circulating cytokines in metastatic breast cancer patients select diferent prognostic groups and patients who might beneft from treatment beyond progression. Vaccines (Basel). 2022; 10(1): 78. doi:10.3390/vaccines10010078.; Yu-Ling L., Hua Z., Xiu-Bao R. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med. 2016; 13(2): 206–14. doi:10.20892/j.issn.2095-3941.2015.0070.; Sun Y., Ai X., Shen S., Gu L., Lu S. Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. Patient Prefer Adherence. 2015; 9: 1165–9. doi:10.2147/PPA.S86605.; Chen W., Qin T., Liu S. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clin Trans Med. 2018; 7(1): 27. doi:10.1186/s40169-018-0205-6.; Jabeen S., Espinoza J.A., Torland L.A., Zucknick M., Kumar S., Haakensen V.D., Lüders T., Engebraaten O., Børresen-Dale A., Kyte J.A., Gromov P., Naume B., Kristensen V., Gromova I., Tekpli X. Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics. OncoImmunology. 2018; 8(2). doi:10.1080/2162402X.2018.1537691.; Kawaguchi K., Sakurai M., Yamamoto Y., Suzuki E., Tsuda M., Kataoka T.R., Hirata M., Nishie M., Nojiri T., Kumazoe M., Saito K., Toi M. Alteration of specifc cytokine expression patterns in patients with breast cancer. Sci Rep. 2019; 9(1): 2924. doi:10.1038/s41598-019-39476-9.; Engel J., Eckel R., Halfter K., Schubert-Fritschle G., Hölzel D. Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. J Cancer Res and Clin Oncol. 2023; 149(2): 721–35. doi:10.1007/s00432-022-04369-4.; Gong G., Kwon M. J., Han J., Lee H.J., Lee S.K., Lee J.E., Lee S.H., Park S., Choi J.S., Cho S.Y., Ahn S.H., Lee J.W., Cho S.R., Moon Y., Nam B.H., Nam S.J., Choi Y.L., Shin Y.K. A new molecular prognostic score for predicting the risk of istant metastasis in patients with HR+/HER2- early breast cancer. Scientifc Reports. 2017; 7. doi:10.1038/srep45554.; Zhang K., Luo Z., Zhang Y., Song X., Zhang L., Wu L., Liu J. Long non-coding RNAs as novel biomarkers for breast cancer invasion and metastasis. Oncology Lett. 2017; 14(2): 1895–904. doi:10.3892/ol.2017.6462.; Lee K.K., Chng W.J., Jha S. Prognostic biomarkers for breast cancer metastasis. Cancer Metastasis. 2018: 96–113. doi:10.5772/intechopen.80576.; Wu X., Baig A., Kasymjanova G., Kaf K., Holcroft C., Mekouar H., Carbonneau A., Bahoric B., Sultanem K., Muanza T. Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus. 2016; 8(12). doi:10.7759/cureus.924.; Ahmed A.A., Hassen A., Osman N., Elroufaie H. Immunohistochemical expression of angiogenic marker CD34 in invasive carcinoma of the breast. Eur Acad Res. 2015; 3(9): 9592–600.; Chen Z., Xu S., Xu W., Huang J., Zhang G.U., Lei L., Shao X., Wang X. Expression of cluster of diferentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic signifcance. Oncol Lett. 2015; 10(2): 723–9. doi:10.3892/ol.2015.3348.; Khan A.A., Alam K., Harris H. A Clinicopathological study of CD34 antigen expression in benign and malignant breast lesions. J Clin Exp Pathol. 2017; 7(4): 321. doi:10.4172/2161-0681.1000321.; Mehdi Hassanpour M., Salybekov A., Kobayashi S., Asahara T. CD34 positive cells as endothelial progenitor cells in biology and medicine. Front Cell Dev Biol. 2023; 17: 11: 1128134. doi:10.3389/fcell.2023.1128134.; Chen M., Sun H., Zhao Y., Fu W., Yang L., Gao S., Li L., Jiang H., Jin W. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: A SEER population-based analysis. Sci Rep. 2017; 7(1). doi:10.1038/s41598-017-10166-8.; Cai S., Zuo W., Lu X., Gou Z., Zhou Y., Liu P., Pan Y., Chen S. The prognostic impact of age at diagnosis upon breast cancer of diferent immunohistochemical subtypes: a surveillance, epidemiology, and end results (SEER) population-based analysis. Front Oncol. 2020; 10: 1729. doi:10.3389/fonc.2020.01729.; Kondov B., Milenkovikj Z., Kondov G., Petrushevska G., Basheska N., Bogdanovska-Todorovska M., Tolevska N., Ivkovski L. Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. J Med Sci. 2018; 6(6): 961–7. doi:10.3889/oamjms.2018.231.; Autenshlyus A., Arkhipov S., Kunts T., Marinkin I., Mikhailova E., Karpukhina X., Varaksin N. Cytokine profles of tumor supernatants in invasive ductal cancer and fbroadenoma of the breast and its relationship with VEGF-A expression in the tumors. Int J Immunopathol Pharmacol. 2017; 30(1): 83–8. doi:10.1177/0394632016681306.; Agilent [Internet]. ER/PR PharmDx Interpretation Manual. URL: https://www.agilent.com/cs/library/usermanuals/public/28252_erpr_pharmdx_interpretation_manual.pdf [cited 01.12.2023].; National Cancer Institute [Internet]. Tumor Grade/ How tumor grade is determined. URL: https://www.cancer.gov/about-cancer/diagnosisstaging/diagnosis/tumor-grade [cited 02.12.2023].; National Cancer Institute [Internet]. Center for Cancer Genomics. The Cancer Genome Atlas Program (TCGA) https://www.cancer.gov/ccg/research/genome-sequencing/tcga [cited 02.12.2023].; Gui P., Bivona T.G. Evolution of metastasis: new tools and insights. Trends Cancer. 2022; 8(2): 98–109. doi:10.1016/j.trecan.2021.11.002.; Reiter J., Makohon-Moore A., Gerold J., Heyde A., Attiyeh M., Kohutek Z., Tokheim C., Brown A., DeBlasio R., Niyazov J., Zucker A., Karchin R., Kinzler R., Iacobuzio-Donahue C., Vogelstein B., Nowak M. Minimal functional driver gene heterogeneity among untreated metastases. Science. 2018; 361(6406): 1033–7. doi:10.1126/science.aat7171.; Bertucci F., Ng C., Patsouris A., Droin N., Piscuoglio S., Carbuccia N., Soria J., Dien A., Adnani Y., Kamal M., Garnier S., Meurice G., Jimenez M., Dogan S., Verret B., Chaffanet M., Bachelot T., Campone M., Lefeuvre C., Bonnefoi H., Dalenc F., Jacquet A., De FilippoM., Babbar N., Birnbaum D., Filleron T., Tourneau C., Andre F. Genomic characterization of metastatic breast cancers. Nature. 2019; 569(7757): 560–4. doi:10.1038/s41586-019-1056-z.; Priestley P., Baber J., Lolkema M., Steeghs N., Bruijn E., Shale C., Duyvesteyn K., Haidari S., Hoeck A., Onstenk W., Roepman P., Voda M., Bloemendal H., Tjan-Heijnen V., Herpen C., Labots M., Witteveen P., Smit E., Sleijfer S., Voest E., Cuppen E. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019; 575(7781): 210–6. doi:10.1038/s41586-019-1689-y.; Markopoulos G., Roupakia E., Marcu K., Kolettas E. Epigenetic regulation of infammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer stem cell generation. Cells. 2019; 8(10). doi:10.3390/cells8101143.; Dai E., Zhu Z., Wahed S., Qu Z., Storkus W.J., Guo Z.S. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021; 20(1): 171. doi:10.1186/s12943-021-01464-x.; Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021; 101(Pt B). doi:10.1016/j.intimp.2021.107598.; The Human Protein Atlas [Internet]. CCL2. Breast cancer. URL: https://www.proteinatlas.org/ENSG00000108691-CCL2/pathology/breast+cancer#imid_3293972 [cited 18.11.2023].; Dong Y., Zhang S., Zhao S., Xuan M., Zhu G., Zhang Z., Guo W. CCL2 promotes lymphatic metastasis via activating RhoA and Rac1 pathway and predict prognosis to some extent in tongue cancer. Cancer Biol Ther. 2023; 24(1). doi:10.1080/15384047.2023.2205342.; The Human Protein Atlas [Internet]. IL18. Breast cancer. URL: https://www.proteinatlas.org/ENSG00000150782-IL18/pathology/ breast+cancer#imid_2204142 [cited 18.11.2023].; https://www.siboncoj.ru/jour/article/view/2839

الاتاحة: https://www.siboncoj.ru/jour/article/view/2839
https://doi.org/10.21294/1814-4861-2023-22-6-92-102

المؤلفون: M. V. Zavyalova, G. A. Kuznetsov, E. S. Grigoryeva, L. A. Tashireva, D. S. Pismenny, V. M. Perelmuter, М. В. Завьялова, Г. А. Кузнецов, Е. С. Григорьева, Л. А. Таширева, Д. С. Письменный, В. М. Перельмутер

المساهمون: The study was supported by the Russian Science Foundation (grant No. 21-15-00140 “Prediction of sites of breast cancer hematogenous metastases”)., Исследование было поддержано Российским научным фондом (грант № 21-15-00140 «Прогнозирование локализации гематогенных метастазов при раке молочной железы»).

المصدر: Siberian journal of oncology; Том 22, № 6 (2023); 103-110 ; Сибирский онкологический журнал; Том 22, № 6 (2023); 103-110 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-0-31-36

مصطلحات موضوعية: первично-метастатический рак, integrins, hematogenous metastases, primary metastatic cancer, интегрины, гематогенные метастазы

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2840/1185; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2021. 252 с.; Su C.Y., Li J.Q., Zhang L.L., Wang H., Wang F.H., Tao Y.W., Wang Y.Q., Guo Q.R., Li J.J., Liu Y., Yan Y.Y., Zhang J.Y. The Biological Functions and Clinical Applications of Integrins in Cancers. Front Pharmacol. 2020; 11. doi:10.3389/fphar.2020.579068.; Bagati A., Kumar S., Jiang P., Pyrdol J., Zou A.E., Godicelj A., Mathewson N.D., Cartwright A.N.R., Cejas P., Brown M., Giobbie-Hurder A., Dillon D., Agudo J., Mittendorf E.A., Liu X.S., Wucherpfennig K.W. Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. Cancer Cell. 2021; 39(1): 54–67. doi:10.1016/j.ccell.2020.12.001.; Sökeland G., Schumacher U. The functional role of integrins during intra- and extravasation within the metastatic cascade. Mol Cancer. 2019; 18(1): 12. doi:10.1186/s12943-018-0937-3.; Kechagia J.Z., Ivaska J., Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment. Nat Rev Mol Cell Biol. 2019; 20(8): 457–73. doi:10.1038/s41580-019-0134-2.; Lokuhetty D., White, V.A., Watanabe R., Cree I.A. WHO Classifcation of Tumours. Breast tumours. Lyon (France): International Agency for Pesearch on Cancer, 2019.; Bertero L., Massa F., Metovic J., Zanetti R., Castellano I., Ricardi U., Papotti M., Cassoni P. Eighth Edition of the UICC Classifcation of Malignant Tumours: an overview of the changes in the pathological TNM classifcation criteria-What has changed and why? Virchows Arch. 2018; 472(4): 519–31. doi:10.1007/s00428-017-2276-y.; Стенина М.Б., Жукова Л.Г., Королева И.А., Пароконная А.А., Семиглазова Т.Ю., Тюляндин С.А., Фролова М.А. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли. 2020; 10(3s2-1): 145–82. doi:10.18027/2224-5057-2020-10-3s2-09.; Truong H.H., Xiong J., Ghotra V.P., Nirmala E., Haazen L., Le Dévédec S.E., Balcioğlu H.E., He S., Snaar-Jagalska B.E., Vreugdenhil E., Meerman J.H., van de Water B., Danen E.H. β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triplenegative breast cancer. Sci Signal. 2014; 7(312). doi:10.1126/scisignal.2004751.; Seguin L., Kato S., Franovic A., Camargo M.F., Lesperance J., Elliott K.C., Yebra M., Mielgo A., Lowy A.M., Husain H., Cascone T., Diao L., Wang J., Wistuba I.I., Heymach J.V., Lippman S.M., Desgrosellier J.S., Anand S., Weis S.M., Cheresh D.A. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014; 16(5): 457–68. doi:10.1038/ncb2953.; Xiong J., Yan L., Zou C., Wang K., Chen M., Xu B., Zhou Z., Zhang D. Integrins regulate stemness in solid tumor: an emerging therapeutic target. J Hematol Oncol. 2021; 14(1): 177. doi:10.1186/s13045-021-01192-1.; Cooper J., Giancotti F.G. Integrin Signaling in Can- cer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3): 347–67. doi:10.1016/j.ccell.2019.01.007.; Böger C., Warneke V.S., Behrens H.M., Kalthoff H., Good- man S.L., Becker T., Röcken C. Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer. 2015; 18(4): 784–95. doi:10.1007/s10120-014-0435-2.; Berghoff A.S., Kovanda A.K., Melchardt T., Bartsch R., Hainfellner J.A., Sipos B., Schittenhelm J., Zielinski C.C., Widhalm G., Dieckmann K., Weller M., Goodman S.L., Birner P., Preusser M. αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clin Exp Metastasis. 2014; 31(7): 841–51. doi:10.1007/s10585-014-9675-0.; Hoshino A., Costa-Silva B., Shen T.L., Rodrigues G., Hashimoto A., Tesic Mark M., Molina H., Kohsaka S., Di Giannatale A., Ceder S., Singh S., Williams C., Soplop N., Uryu K., Pharmer L., King T., Bojmar L., Davies A.E., Ararso Y., Zhang T., Zhang H., Hernandez J., Weiss J.M., Dumont-Cole V.D., Kramer K., Wexler L.H., Narendran A., Schwartz G.K., Healey J.H., Sandstrom P., Labori K.J., Kure E.H., Grandgenett P.M., Hollingsworth M.A., de Sousa M., Kaur S., Jain M., Mallya K., Batra S.K., Jarnagin W.R., Brady M.S., Fodstad O., Muller V., Pantel K., Minn A.J., Bissell M.J., Garcia B.A., Kang Y., Rajasekhar V.K., Ghajar C.M., Matei I., Peinado H., Bromberg J., Lyden D. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527(7578): 329–35. doi:10.1038/nature15756.; https://www.siboncoj.ru/jour/article/view/2840

الاتاحة: https://www.siboncoj.ru/jour/article/view/2840
https://doi.org/10.21294/1814-4861-2023-22-6-103-110

المؤلفون: I. M. Gelfand, M. A. Kropotov, M. T. Isaeva, S. O. Podvyaznikov, И. М. Гельфанд, М. А. Кропотов, М. Т. Исаева, С. О. Подвязников

المساهمون: The work was performed without external funding, Работа выполнена без спонсорской поддержки

المصدر: Head and Neck Tumors (HNT); Том 13, № 4 (2023); 116-123 ; Опухоли головы и шеи; Том 13, № 4 (2023); 116-123 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2023-13-4

مصطلحات موضوعية: регионарные метастазы, signal lymph nodes, biopsy of signal lymph node, regional metastases, сигнальные лимфатические узлы, биопсия сигнального лимфатического узла

وصف الملف: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/943/612; Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166(5):1069–80. DOI:10.1111/j.1365-2133.2012.10830.x; Leiter U., Eigentler T., Garbe C. Epidemiology of skin cancer. Sunlight, vitamin D and skin cancer. NY: Springer, 2014. Pp. 120–140.; Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. 250 с.; Stratigos A., Garbe C., Lebbe C. et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015;51(14):1989–2007. DOI:10.1016/j.ejca.2015.06.110; Trakatelli M., Ulrich C., del Marmol V. et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007;156(3):1–7. DOI:10.1111/j.1365-2133.2007.07861.x; Albert A., Knoll M.A., Conti J.A., Zbar R.I.S. Non-melanoma skin cancers in the older patient. Curr Oncol Rep 2019;21(9):79. DOI:10.1007/s11912-019-0828-9; Stratigos A.J., Garbe C., Dessinioti C. et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin. Part 1. Epidemiology, diagnostics and prevention Eur J Cancer 2020;128:60–82. DOI:10.1016/j.ejca.2020.01.007; Gordon L.G., Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening : a systematic review. Eur J Cancer Prev 2015;24(2):141–9. DOI:10.1097/CEJ.0000000000000056; Actinic keratosis: overview. Available at: http://www.skincarephysicians.com/actinickeratosesnet/whatAre.htm.; Nguyen T.H., Ho D.Q. Nonmelanoma skin cancer. Curr Treat Options Oncol 2002;3(3):193–203. DOI:10.1007/s11864-002-0009-0; Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001;63(1–3):8–18. DOI:10.1016/s1011-1344(01)00198-1; Glass A.G., Hoover R.N. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989;262(15):2097–100.; Veness M.J., Morgan G.J., Palme C.E., Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005;115(5):870–5. DOI:10.1097/01.MLG.0000158349.64337.ED; Rowe D.E., Carroll R.J., Day C.L. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol 1992;26(6):976–90. DOI:10.1016/0190-9622(92)70144-5; Karia P.S., Han J., Schmults C.D. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013;68(6):957–66. DOI:10.1016/j.jaad.2012.11.037; Mooney C.P., Martin R.C.W., Dirven R. et al. Sentinel node biopsy in 105 high-risk cutaneous SCCs of the head and neck: results of a multicenter prospective study. Ann Surg Oncol 2019;26(13):4481–8. DOI:10.1245/s10434-019-07865-z; Lewis K.G., Weinstock M.A. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007;127(10):2323–7. DOI:10.1038/sj.jid.5700897; Janković I., Kovačević P., Janković D. et al. Lymphatic drainage map of the head and neck skin squamous cell carcinoma detected by sentinel lymph node biopsy. Eur Rev Med Pharmacol Sci2021;25(16):5228–34. DOI:10.26355/eurrev_202108_26536; Veness M.J., Porceddu S., Palme C.E., Morgan G.J. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 2007;29(7):621–31. DOI:10.1002/hed.20576; Veness M.J., Palme C.E., Morgan G.J. High-risk cutaneous squamous cell carcinoma of the head and neck. Cancer 2006;106(11):2389–96. DOI:10.1002/cncr.21898; Thompson A.K., Kelley B.F., Prokop L.J. et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 2016;152(4):419–28. DOI:10.1001/jamadermatol.2015.4994; Schmults C.D., Karia P.S., Carter J.B. et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013;149(5):541–7. DOI:10.1001/jamadermatol.2013.2139; O’Brien C.J., McNeil E.N., McMahon J.D. et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002;24(5):417–22. DOI:10.1002/hed.10063; Ross A.S., Schmults C.D. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma : a systematic review of the english literature. Dermatol Surg 2006;32(11):1309–21. DOI:10.1111/j.1524-4725.2006.32300.x; Gallagher R.P., Hill G.B., Bajdik C.D. et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995;131(2):157–63.; Franceschi S., Levi F., Randimbison L., La Vecchia C. Site distribution of different types of skin cancer: new aetiological clues. Int J Cancer 1996;3(1):4–8. DOI:10.1002/(SICI)1097-0215(19960703)67:13.0.CO;2-1; Nouri K., Rivas M.P., Pedroso F. et al. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Arch Dermatol 2004;140(10):1284. DOI:10.1001/archderm.140.10.1284-a; Nuno-Gonzalez A., Vicente-Martin F.J., Pinedo-Moraleda F., Lopez-Estebaranz J.L. High-risk cutaneous squamous cell carcinoma. Actas Dermosifiliogr 2012;103:567–78. DOI:10.1016/J.ADENGL.2012.08.004; Navarrete-Dechent C., Veness M.J., Droppelmann N., Uribe P. Highrisk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy : a literature review. J Am Acad Dermatol 2015;73(1):127–37. DOI:10.1016/j.jaad.2015.03.039; Brantsch K.D., Meisner C., Schonfisch B. et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008;9(8):713–20. DOI:10.1016/S1470-2045(08)70178-5; Veness M.J. Defining patients with high-risk cutaneous squamous cell carcinoma. Australas J Dermatol 2006;47(1):28–33. DOI:10.1111/j.1440-0960.2006.00218.x; Eigentler T.K., Leiter U., Hafner H.M. et al. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study. J Invest Dermatol 2017;137(11):2309–15. DOI:10.1016/j.jid.2017.06.025; Кaria P.S., Morgan F.C., Ruiz E.S., Schmults C.D. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma : а systematic review and pooled analysis of outcomes data. JAMA Dermatol 2017;153(8):781–8. DOI:10.1001/jamadermatol.2017.1680; Moore B.A., Weber R.S., Prieto V. et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck Lary ngoscope2005;115(9):1561–7. DOI:10.1097/01.mlg.0000173202.56739.9f; Manyam B.V., Garsa A.A., Chin R.I. et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer 2017;123(11):2054–60. DOI:10.1002/cncr.30601; Oddone N., Morgan G.J., Palme C.E. et al. Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer 2009;115(9):1883–91. DOI:10.1002/cncr.24208; Zavos G., Karidis N.P., Tsourouflis G., Bokos J. et al. Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations. Int J Dermatol 2011;50(12):1496–500. DOI:10.1111/j.1365-4632.2011.04939.x; Renzi C., Caggiati A., Mannooranparampil T.J. et al. Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 2007;33(3):364–9. DOI:10.1016/j.ejso.2006.10.017; Martorell-Calatayud A., Sanmartín Jimenez O., Cruz Mojarrieta J., Guillén Barona C. Cutaneous squamous cell carcinoma: defining the high-risk variant. Actas Dermosifiliogr 2013;104(5):367–79. DOI:10.1016/j.adengl.2011.12.012; Zwald F.O., Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011;65(2):253–61. DOI:10.1016/j.jaad.2010.11.062; Kwon S., Dong Z.M., Wu P.C. Sentinel lymph node biopsy for highrisk cutaneous squamous cell carcinoma : clinical experience and review of literature. World J Surg Oncol 2011;9:80. DOI:10.1186/1477-7819-9-80; American Joint Committee on Cancer. Cutaneous squamous cell carcinoma and other cutaneous carcinomas. 7 th ed. NY: Springer, 2010.; Stoff B., Salisbury C., Parker D., O’Reilly Zwald F. Dermatopathology of skin cancer in solid organ transplant recipients. Transplant Rev (Orlando) 2010:24(4):172–89. DOI:10.1016/j.trre.2010.05.002; Brougham N.D., Tan S.T. The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma – implications on the T-classification system. J Surg Oncol 2014;110(7):876–82. DOI:10.1002/jso.23731; Tomaszewski J.M., Gavriel H., Link E. et al. Aggressive behavior of cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Laryngoscope 2014;124(9):2043–8. DOI:10.1002/lary.24586; Martinez J.C., Otley C.C., Stasko T. et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a mul ticenter collaborative study. Arch Dermatol 2003;139(3): 301–6. DOI:10.1001/archderm.139.3.301; Friedman N.R. Prognostic factors for local recurrence, metastases, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol 1993;28(2 Pt. 1):281–2. DOI:10.1016/s0190-9622(08)81164-4; Peat B., Insull P., Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg 2012;82(4):230–3. DOI:10.1111/j.1445-2197.2011.05994.x; Shen R., Zhang J., Zhang F. et al. Clinical characteristics and therapeutic analysis of 51 patients with Marjolin’s ulcers. Exp Ther Med 2015;10(4):1364–74. DOI:10.3892/etm.2015.2699; Breuninger H., Schaumburg-Lever G., Holzschuh J., Horny H.P. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer 1997;79(5):915–9. DOI:10.1002/(sici)1097-0142(19970301)79:53.0.co;2-a; Garcia-Pedrero J.M., Martinez-Camblor P., Diaz-Coto S. et al. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 2017;77(3):527–33. DOI:10.1016/j.jaad.2017.05.047; Wong W.K., Morton R.P. Elective management of cervical and parotid lymph nodes in stage N0 cutaneous squamous cell carcinoma of the head and neck: a decision analysis. Eur Arch Otorhinolaryngol 2014;271(11):3011–9. DOI:10.1007/s00405-013-2857-6; Skulsky S.L., O’Sullivan B., McArdle O. et al. Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. Head Neck 2017;39(3):578–94. DOI:10.1002/hed.24580; Kadakia S., Saman M., Gordin E. et al. The role of parotidectomy in the treatment of auricular squamous cell carcinoma. Otolaryngol Head Neck Surg 2015;152(6):1048–52. DOI:10.1177/0194599815579885; Martinez J.C., Cook J.L. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection? Dermatol Surg 2007;33(4):410–20. DOI:10.1111/j.1524-4725.2007.33087.x; Amit M., Liu C., Mansour J. et al. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer 2021;127(23):4413–20. DOI:10.1002/cncr.33773; Staples M.P., Elwood M., Burton R.C. et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006;184(1):6–10. DOI:10.5694/j.1326-5377.2006.tb00086.x; Fukushima S., Masuguchi S., Igata T. et al. Evaluation of sentinel node biopsy for cutaneous squamous cell carcinoma. J Dermatol 2014;41(6):539–41. DOI:10.1111/1346-8138.12508; Forest V.I., Clark J.J., Veness M.J., Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer 2010;116(5):1298–304. DOI:10.1002/cncr.24855; Allen J.E., Stolle L.B. Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2015;41(2):197–200. DOI:10.1016/j.ejso.2014.10.055; Ahadiat O., Higgins S., Sutton A. et al. SLNB in cutaneous SCC : A review of the current state of literature and the direction for the future. J Surg Oncol 2017;116:344–50.; Gore S.M., Shaw D., Martin R.C. et al. Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2016;38(Suppl. 1): E884–9. DOI:10.1002/hed.24120; Navarrete-Dechent C., Veness M.J., Droppelmann N., Uribe P. Cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy. G Ital Dermatol Venereol 2018;153(3):403–18. DOI:10.23736/S0392-0488.18.05936-9; Lubov J., Labbé M., Sioufi K. et al. Prognostic factors of head and neck cutaneous squamous cell carcinoma : a systematic review. J Otolaryngol Head Neck Surg 2021;50(1):54. DOI:10.1186/s40463-021-00529-7; Durham A.B., Lowe L., Malloy K.M. et al. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma on the head and neck. JAMA Otolaryngol Head Neck Surg 2016;142(12):1171–6. DOI:10.1001/jamaoto.2016.1927; Schmults C.D. NCCN Clinical Practice Guidelines in Oncology. Squamous cell skin cancer, version 1.2022 J Natl Compr Canc Netw 2021;19(12):1382–94. DOI:10.6004/jnccn.2021.0059; Haisma M.S., Plaat B.E C., Bijl H.P. et al. Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 2016;75(4):722–30. DOI:10.1016/j.jaad.2016.06.010; Yesensky J. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma of the head and neck. 2023. Available at: https://clinicaltrials.gov/study/NCT05108090.; https://ogsh.abvpress.ru/jour/article/view/943

الاتاحة: https://ogsh.abvpress.ru/jour/article/view/943
https://doi.org/10.17650/2222-1468-2023-13-4-116-123

المؤلفون: D. V. Gavrilyuk, R. A. Zukov, Д. В. Гаврилюк, Р. А. Зуков

المصدر: Head and Neck Tumors (HNT); Том 14, № 1 (2024); 56-62 ; Опухоли головы и шеи; Том 14, № 1 (2024); 56-62 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2024-14-1

مصطلحات موضوعية: метастазы папиллярной аденокарциномы, aberrant struma, thyroid cancer, papillary adenocarcinoma metastases, аберрантная струма, рак щитовидной железы

وصف الملف: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/969/620; Альмяшев А.З. Эктопированная щитовидная железа: обзор литературы и анализ клинического наблюдения. Опухоли головы и шеи 2013;4:10-4. DOI:10.17650/2222-1468-2013-0-4-10-14; Бронштейн М.Э. Морфологическая диагностика заболеваний щитовидной железы (лекция). Проблемы эндокринологии 1999;45(5):34-8.; Зима Д.В., Алиев М.А., Кульбаба П.В. и др. Эктопия щитовидной железы: механизмы и клинические наблюдения. Крымский журнал экспериментальной и клинической медицины 2019;9(4):44-9.; Безруков О.Ф., Зима Д.В., Михайличенко В.Ю., Хабаров О.Р. Аберрантный зоб (клинические наблюдения). Практическая медицина 2019;17(4):170—3. DOI:10.32000/2072-1757-2019-4-170-173; Шрёдер Е.В., Вадина Т.А., Конюхова М.Б. и др. Эктопия щитовидной железы: особенности клиники и диагностики у детей. Проблемы эндокринологии 2022; 68(3):76—85. DOI:10.14341/probl12876; Макрецкая Н.А., Безлепкина О.Б., Колодкина А.А. и др. Молекулярно-генетические основы дисгенезии щитовидной железы. Клиническая и экспериментальная тиреоидология 2018;14(2):64-71. DOI:10.14341/ket9556; Пинский С.Б., Дворниченко В.В., Репета О.Р. Рак щитовидно-язычного протока. Сибирский медицинский журнал 2008;3:5-7.; Клочихин А.Л., Бырихина В.В., Марков Г.И. Рак щитоязычного протока. Вестник оториноларингологии 2018;6:46-7.; Петров В.Г., Якимов С.А., Ивашина Е.Г., Бастракова С.Г. Клиническое наблюдение истинного бокового аберрантного зоба. Эндокринная хирургия 2012;1:44-7.; Галушко Д.А., Асмарян А.Г., Мельникова Н.В., Лазукина И.А. Клиническое значение особенностей морфологического исследования и иммуногистохимического определения панцито-кератина в лимфатических узлах центральной зоны при папиллярном раке щитовидной железы. Опухоли головы и шеи 2022;12(3):17-27. DOI:10.17650/2222-1468-2022-12-3-17-27; Титов С.Е., Катанян Г.А., Полоз Т.Л. и др. Дооперационное выявление метастазов папиллярного и медуллярного рака щитовидной железы в шейных лимфатических узлах с помощью молекулярного классификатора. Опухоли головы и шеи 2020;10(4):50-9. DOI:10.17650/2222-1468-2020-10-4-50-59; Паршин В.С., Веселова А.А., Медведев В.С. и др. Ультразвуковая диагностика метастазов в лимфатических узлах шеи II-IV уровней у больных с впервые установленным диагнозом папиллярного рака щитовидной железы. Опухоли головы и шеи 2019;9(4):17-23. DOI:10.17650/2222-1468-2019-9-4-17-23; Субраманиан С., Любаев В.Л., Бржезовский В.Ж., Айдарбекова А.А. Классификация лимфатических узлов шеи: необходимость перехода на современную классификацию в онкологической практике. Вестник РОНЦ им. Н.Н. Блохина РАМН 2006;17(3):54-9.; https://ogsh.abvpress.ru/jour/article/view/969

الاتاحة: https://ogsh.abvpress.ru/jour/article/view/969
https://doi.org/10.17650/2222-1468-2024-14-1-56-62

المؤلفون: A. Yu. Goryainova, S. V. Sharov, O. I. Kirsanova, O. A. Goncharova, R. A. Murashko, А. Ю. Горяинова, С. В. Шаров, О. И. Кирсанова, О. А. Гончарова, Р. А. Мурашко

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2024); 46-53 ; Медицинский Совет; № 10 (2024); 46-53 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: трастузумаб дерукстекан, HER2/neu, brain metastases, leptomeningeal metastasis, trastuzumab deruxtecan, метастазы в головной мозг, лептоменингеальное метастазирование

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8393/7383; Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triplenegative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–2645. https://doi.org/10.1002/cncr.23930.; Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012;136(1):153–160. https://doi.org/10.1007/s10549-012-2243-x.; Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–3277. https://doi.org/10.1200/JCO.2009.25.9820.; Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244–248. https://doi.org/10.1016/S1470-2045(13)70017-2.; DeSantis C, Jemal A, Ward E. Disparities in breast cancer prognostic factors by race, insurance status, and education. Cancer Causes Control. 2010;21(9):1445–1450. https://doi.org/10.1007/s10552-010-9572-z.; Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–514. https://doi.org/10.1007/s10549-013-2711-y.; Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G et al. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020;25(2):e214-e222. https://doi.org/10.1634/theoncologist.2019-0446.; Chen X, Wang J, Fan Y, Luo Y, Zhang P, Li Q et al. Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. Clin Breast Cancer. 2021;21(3):191–198. https://doi.org/10.1016/j.clbc.2020.09.003.; Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. https://doi.org/10.1056/NEJM200103153441101.; Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924–934. https://doi.org/10.1634/theoncologist.2009-0181.; Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124.; Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–1130. https://doi.org/10.1200/JCO.2008.21.4437.; Ibragimova KIE, Geurts SME, Croes S, Erdkamp F, Heijns JB, Tol J et al. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Res Treat. 2021;188(2):571–581. https://doi.org/10.1007/s10549-021-06178-8.; Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016;160(1):187–196. https://doi.org/10.1007/s10549-016-3978-6.; Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review. Breast Cancer Res. 2015;17:140. https://doi.org/10.1186/s13058-015-0648-2.; Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018;181:126–142. https://doi.org/10.1016/j.pharmthera.2017.07.013.; Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–5108. https://doi.org/10.1158/1078-0432.CCR-15-2822.; Ku GY, Ilson DH. Chemotherapeutic options for gastroesophageal junction tumors. Semin Radiat Oncol. 2013;23(1):24–30. https://doi.org/10.1016/j.semradonc.2012.09.003.; Stintzing S. Management of colorectal cancer. F1000Prime Rep. 2014;6:108. https://doi.org/10.12703/P6-108.; Sudo K, Yamada Y. Advancing pharmacological treatment options for advanced gastric cancer. Expert Opin Pharmacother. 2015;16(15):2293–2305. https://doi.org/10.1517/14656566.2015.1080238.; Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802. https://doi.org/10.1038/nrc1977.; Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173–185. https://doi.org/10.1248/cpb.c18-00744.; Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–1046. https://doi.org/10.1111/cas.12966.; Yin O, Iwata H, Lin CC, Tamura K, Watanabe J, Wada R et al. ExposureResponse Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Clin Pharmacol Ther. 2021;110(4):986–996. https://doi.org/10.1002/cpt.2291.; Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–826. https://doi.org/10.1016/S1470-2045(19)30097-X.; Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al.; DESTINYBreast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621. https://doi.org/10.1056/NEJMoa1914510.; Saura C, Modi S, Krop I, Park YH, Kim S, Tamura K et al. 279P – Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2021;32(Suppl. 5):S485–S486. https://doi.org/10.1016/j.annonc.2021.08.562.; Hamilton E, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. J Clin Oncol. 2024;42(16 Suppl):1025. https://doi.org/10.1200/JCO.2024.42.16_suppl.1025.; Hurvitz SA, Hegg R, Chung WP, Wei-Pang, Im SA, Jacot W et al. Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. Cancer Res. 2023;83(5 Suppl):GS2-02. https://doi.org/10.1158/1538-7445.SABCS22-GS2-02.; Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R et al.; DESTINYBreast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143–1154. https://doi.org/10.1056/NEJMoa2115022.; Nguyen A, Nguyen A, Dada OT, Desai PD, Ricci JC, Godbole NB et al. Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape. Curr Oncol. 2023;30(6):5906–5931. https://doi.org/10.3390/curroncol30060442.; Le Rhun E, Preusser M, van den Bent M, Andratschke N, Weller M. How we treat patients with leptomeningeal metastases. ESMO Open. 2019;4(Suppl. 2):e000507. https://doi.org/10.1136/esmoopen-2019-000507.; de Bernardi A, Bachelot T, Larrouquère L. Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature. Front Oncol. 2024;13:1210873. https://doi.org/10.3389/fonc.2023.1210873.; Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. https://doi.org/10.1016/S1470-2045(12)70432-1.; Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer. 2010;102(6):995–1002. https://doi.org/10.1038/sj.bjc.6605586.; Wilcox JA, Li MJ, Boire AA. Leptomeningeal Metastases: New Opportunities in the Modern Era. Neurotherapeutics. 2022;19(6):1782–1798. https://doi.org/10.1007/s13311-022-01261-4.; https://www.med-sovet.pro/jour/article/view/8393

الاتاحة: https://www.med-sovet.pro/jour/article/view/8393
https://doi.org/10.21518/ms2024-252

المؤلفون: E. V. Reutova, K. K. Laktionov, M. A. Ardzinba, Е. В. Реутова, К. К. Лактионов, М. С. Ардзинба

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2024); 60-65 ; Медицинский Совет; № 10 (2024); 60-65 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: метастазы в центральной нервной системе, ALK translocation, targeted therapy, ceritinib, CNS metastases, транслокация ALK, таргетная терапия, церитиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8394/7385; Демидова ИА, Цепенщикова ЕО, Баринов АА, Гагарин ИМ, Савелов НА, Гриневич ВН, Тюляндин СА. Определение перестроек гена ALK в селектированной популяции российских больных немелкоклеточным раком легкого. Злокачественные опухоли. 2013;(3):3–9. https://doi.org/10.18027/2224-5057-2013-3-3-9.; Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 2009;27(26):4232–4235. https://doi.org/10.1200/JCO.2009.23.6661.; Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006. https://doi.org/10.1001/jama.2014.3741.; Лактионов КК, Артамонова ЕВ, Бредер ВВ, Горбунова ВА, Демидова ИА, Деньгина НВ и др. Немелкоклеточный рак легкого. Злокачественные опухоли. 2023;13(3s2-1):42–65. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-42-65.; Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929. https://doi.org/10.1016/S0140-6736(17)30123-X.; Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–463. https://doi.org/10.1016/S1470-2045(15)00614-2.; Chow LQM, Barlesi F, Bertino EM, van den Bent MJ, Wakelee HA, Wen PY et al. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clin Cancer Res. 2022;28(12):2506–2516. https://doi.org/10.1158/1078-0432.CCR-21-1838.; Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G et al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357–1367. https://doi.org/10.1016/j.jtho.2017.07.005.; Otoukesh S, Sanchez T, Mirshahidi S, Wallace D, Mirshahidi H. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective. Cancer Treat Res Commun. 2019;20:100149. https://doi.org/10.1016/j.ctarc.2019.100149.; Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol. 2016;34(24):2866–2873. https://doi.org/10.1200/JCO.2015.65.5936.; Li J, Knoll S, Bocharova I, Tang W, Signorovitch J. Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls. Curr Med Res Opin. 2019;35(1):105–111. https://doi.org/10.1080/03007995.2018.1541443.; Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R et al. Molecular Mechanisms of Resistance to Firstand Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016;6(10):1118–1133. https://doi.org/10.1158/2159-8290.CD-16-0596.; Fukui T, Tachihara M, Nagano T, Kobayashi K. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Cancers (Basel). 2022;14(5):1184. https://doi.org/10.3390/cancers14051184.; Hansen KH, Johansen JS, Urbanska EM, Meldgaard P, Hjorth-Hansen P, Kristiansen C et al. Clinical outcomes of ALK+ non-small cell lung cancer in Denmark. Acta Oncol. 2023;62(12):1775–1783. https://doi.org/10.1080/0284186X.2023.2263153.; Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–1064. https://doi.org/10.1016/j.annonc.2020.04.478.; Lenderking WR, Lin H, Speck RM, Zhu Y, Huang H, Huang J et al. Patientreported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA). Future Oncol. 2019;15(24):2841–2855. https://doi.org/10.2217/fon-2019-0185.; Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354–366. https://doi.org/10.1016/S2213-2600(22)00437-4.; Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10(2):232–236. https://doi.org/10.1097/JTO.0000000000000455.; https://www.med-sovet.pro/jour/article/view/8394

الاتاحة: https://www.med-sovet.pro/jour/article/view/8394
https://doi.org/10.21518/ms2024-238

المؤلفون: A. V. Solovieva, O. M. Uryasev, O. V. Kodyakova, M. S. Bolotina, I. V. Vasin, E. M. Shurpo, А. В. Соловьева, О. М. Урясьев, О. В. Кодякова, М. С. Болотина, И. В. Васин, Е. М. Шурпо

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 181-187 ; Медицинский Совет; № 22 (2023); 181-187 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: эндоскопическая диагностика, metastatic melanoma, spontaneous regression of cutaneous melanoma, visceral metastases, endoscopic diagnostics, метастатическая меланома, спонтанная регрессия меланомы кожи, висцеральные метастазы

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7994/7082; Marks R. Epidemiology of melanoma. Clin Exp Dermatol. 2000;25(6):459–463. https://doi.org/10.1046/j.1365-2230.2000.00693.x.; Малишевская НП, Соколова АВ, Демидов ЛВ. Современное состояние заболеваемости меланомой кожи в Российской Федерации и федеральных округах. Медицинский совет. 2018;(10):161–165. https://doi.org/10.21518/2079-701X-2018-10-161-165.; Sundararajan S, Thida AM, Yadlapati S, Koya S. Metastatic Melanoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://pubmed.ncbi.nlm.nih.gov/29262232.; Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, Bar-Eli M. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 2014;27(1):19–36. https://doi.org/10.1111/pcmr.12172.; Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;(16):647684. https://doi.org/10.1155/2012/647684.; Lee MH, Zaheer A, Voltaggio L, Johnson PT, Fishman EK. Clinical time course and CT detection of metastatic disease to the small bowel. Abdom Radiol (NY). 2019;44(6):2104–2110. https://doi.org/10.1007/s00261-019-01957-w.; Silva S, Tenreiro N, Melo A, Lage J, Moreira H, Próspero F, Avelar P. Metastatic melanoma: An unusual cause of gastrointestinal bleeding and intussusception-A case report. Int J Surg Case Rep. 2018;53:144–146. https://doi.org/10.1016/j.ijscr.2018.10.057.; Gilg MM, Gröchenig HP, Schlemmer A, Eherer A, Högenauer C, Langner C. Secondary tumors of the GI tract: origin, histology, and endoscopic findings. Gastrointest Endosc. 2018;88(1):151–158.e1. https://doi.org/10.1016/j.gie.2018.02.019.; Schizas D, Tomara N, Katsaros I, Sakellariou S, Machairas N, Paspala A et al. Primary gastric melanoma in adult population: a systematic review of the literature. ANZ J Surg. 2021;91(3):269–275. https://doi.org/10.1111/ans.16160.; Farshad S, Keeney S, Halalau A, Ghaith G. A Case of Gastric Metastatic Melanoma 15 Years after the Initial Diagnosis of Cutaneous Melanoma. Case Rep Gastrointest Med. 2018;2018:7684964. https://doi.org/10.1155/2018/7684964.; Кабанов МЮ, Семенцов КВ, Дегтерев ДБ, Беликова МЯ, Савченков ДК, Кошелев ТЕ, Стечишина АК. Эндоскопическое выявление метастатического поражения желудка при меланоме кожи. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):63–68. https://doi.org/10.22416/1382-4376-2020-30-6-63-68.; Serrao EM, Costa AM, Ferreira S, McMorran V, Cargill E, Hough C et al. The different faces of metastatic melanoma in the gastrointestinal tract. Insights Imaging. 2022;13(1):161. https://doi.org/10.1186/s13244-022-01294-5.; Kohoutova D, Worku D, Aziz H, Teare J, Weir J, Larkin J. Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. Cells. 2021;10(2):327. https://doi.org/10.3390/cells10020327.; Augustyn A, de Leon ED, Yopp AC. Primary gastric melanoma: case report of a rare malignancy. Rare Tumors. 2015;7(1):5683. https://doi.org/10.4081/rt.2015.5683.; Тонеев ЕА, Чарышкин АЛ, Деньгина НВ, Жинов АВ, Мартынов АА, Городнов СВ, Лазаревский ММ. Случай первичной меланомы желудка. Злокачественные опухоли. 2020;10(1):35–40. https://doi.org/10.18027/2224-5057-2020-10-35-40.; Израилов РЕ, Титов КС, Кононец ПВ, Кошкин МА, Ротин ДЛ, Драпун СВ. Первичная меланома пищевода. Хирургия. Журнал им. Н.И. Пирогова. 2018;(5):110–111. https://doi.org/10.17116/hirurgia20185110-111.; Wang S, Sun S, Liu X, Ge N, Wang G, Guo J et al. Endoscopic diagnosis of gastrointestinal melanoma. Scand J Gastroenterol. 2020;55(3):330–337. https://doi.org/10.1080/00365521.2020.1734074.; La Selva D, Kozarek RA, Dorer RK, Rocha FG, Gluck M. Primary and metastatic melanoma of the GI tract: clinical presentation, endoscopic findings, and patient outcomes. Surg Endosc. 2020;34(10):4456–4462. https://doi.org/10.1007/s00464-019-07225-8.; Матвиенко НА, Кудрявицкий ЕЕ, Перфильев ИБ, Кувшинов ЮП, Унгиадзе ГВ. Эндоскопическая диагностика меланомы верхних отделов желудочно-кишечного тракта. Поволжский онкологический вестник. 2016;(4):43–51. Режим доступа: http://oncovestnik.ru/archive/2016/2016-4/diagnostika-melanomy-verkhnikh-otdelov-zheludochno-kishechnogo-trakta.; Zhang X, Li M, Lan X. Melanin-Targeted PET Imaging With 18F-PFPN for Identifying Gastric Metastatic Melanoma. Clin Nucl Med. 2022;47(7):666–667. https://doi.org/10.1097/RLU.0000000000004237.; Genova P, Sorce M, Cabibi D, Genova G, Gebbia V, Galanti D et al. Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy. Case Rep Oncol Med. 2017;2017:2079068. https://doi.org/10.1155/2017/2079068.; Романова О. Роль врача первичного звена в ранней диагностике меланомы кожи. Врач. 2016;(2):49–51. Режим доступа: https://vrachjournal.ru/ru/25877305-2016-02-17.; Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer Journal. 2012;18(2):176–184. https://doi.org/10.1097/PPO.0b013e31824bc981.; O’Sullivan DE, Boyne DJ, Gogna P, Brenner DR, Cheung WY. Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada. Curr Oncol. 2023;30(4):4166–4176. https://doi.org/10.3390/curroncol30040317.; Enomoto LM, Levine EA, Shen P, Votanopoulos KI. Role of Surgery for Metastatic Melanoma. Surg Clin North Am. 2020;100(1):127–139. https://doi.org/10.1016/j.suc.2019.09.011.; Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–2555. https://doi.org/10.1245/s10434-012-2398-z.; Ахмедов СМ, Сафаров БД, Табаров ЗВ, Наврузов ОФ. Резекция печени при метастазе меланомы. Российский медико­биологический вестник им. академика И.П. Павлова. 2016;24(3):103–107. https://doi.org/10.17816/PAVLOVJ20163103-107.; Zhang JY, Gao WD, Lin JY, Xu S, Zhang LJ, Lu XC et al. Nanotechnology-based photo-immunotherapy: a new hope for inhibition of melanoma growth and metastasis. J Drug Target. 2023;31(6):555–568. https://doi.org/10.1080/1061186X.2023.2216402.; D’Alise AM, Scarselli E. Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. Curr Opin Oncol. 2023;35(2):94–99. https://doi.org/10.1097/CCO.0000000000000923.; https://www.med-sovet.pro/jour/article/view/7994

الاتاحة: https://www.med-sovet.pro/jour/article/view/7994
https://doi.org/10.21518/ms2023-443

المؤلفون: M. Yu. Rykov, M. G. Venediktova, М. Ю. Рыков, М. Г. Венедиктова

المصدر: Malignant tumours; Принято в печать ; Злокачественные опухоли; Принято в печать ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: онкогинекология, skin metastases, oncology, oncogynecology, метастазы в кожу, онкология

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1300/931; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: «МНИОИ им. П.А. Герцена» – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.252 с.; Creasman W.T., Ali S., Mutch D.G., et al. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol 2017;145(3):519–525. https://doi.org/10.1016/j.ygyno.2017.03.017; Фадеева Е.П., Лисянская А.С., Манихас Г.М. и соавт. Ингибиторы ароматазы третьего поколения в эндокринотерапии рака молочной железы и рака эндометрия: успехи и неудачи комбинированной терапии. Обзоры по клинической фармакологии и лекарственной терапии 2016;14(2):47–57. https://doi.org/10.17816/RCF14247-57; Elit L., Lukka H., Friedman E. Cutaneous metastasis of papillary serous uterine cancer. Gynecol Oncol 2001;82(1):208–11. https://doi.org/10.1006/gyno.2001.6224; Clairwood M., Yasuda M., Belazarian L., Deng A. Unusual Cutaneous Metastasis of Uterine Carcinosarcoma: A Case Report and Review of the Literature. Am J Dermatopathol 2016;38(5):366–9. https://doi.org/10.1097/DAD.0000000000000476; Samaila M.O., Adesiyun A.G., Waziri G.D., et al. Cutaneous umbilical metastases in post-menopausal females with gynaecological malignancies. J Turk Ger Gynecol Assoc 2012;13(3):204–7. https://doi.org/10.5152/jtgga.2012.29; Ma X.G., Wang Y.M., Sheng H.N., et al. Endometrial cancer metastasize to the skin of lower leg and vagina: case report and literature review. Eur J Gynaecol Oncol 2013;34(4):350–2. PMID: 24020146; Mitchell E., Ciccone M., Zhang B., et al. Paraneoplastic Cushing’s syndrome and hypercalcemia arising from metastatic endometrioid endometrial adenocarcinoma: A case report. Gynecol Oncol Rep 2019;29:58–60. https://doi.org/10.1016/j.gore.2019.06.005; https://www.malignanttumors.org/jour/article/view/1300

الاتاحة: https://www.malignanttumors.org/jour/article/view/1300

المؤلفون: V. А. Yarovaya, А. V. Golanov, V. V. Nazarova, А. R. Zaretskii, I. А. Levashov, А. К. Kulagina, Т. V. Melnikova, А. D. Matyaeva, А. А. Yarovoy, В. А. Яровая, А. В. Голанов, В. В. Назарова, А. Р. Зарецкий, И. А. Левашов, А. К. Кулагина, Т. В. Мельникова, А. Д. Матяева, А. А. Яровой

المصدر: Malignant tumours; Том 14, № 1 (2024); 83-91 ; Злокачественные опухоли; Том 14, № 1 (2024); 83-91 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: клинический случай, fine needle aspiration biopsy, molecular testing, prognostic classes, Gamma Knife stereotactic radiosurgery, surveillance for metastatic disease, liver metastases, case report, тонкоигольная аспирационная биопсия, молекулярно-генетическое тестирование, прогностические классы, стереотаксическая радиохирургия «Гамма-нож», мониторинг метастатической болезни, метастазы в печени

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1289/919; Яровой А.А., Голанов А.В., Ильялов С.Р. и соавт. Стереотаксическая радиохирургия «Гамма-нож» как альтернатива энуклеации у пациентов с увеальной меланомой (первые результаты). Офтальмохирургия 2014;2:74–80.; Яровой А.А., Демидов Л.В., Зарецкий А.Р., Яровая В.А., Назарова В.В., Чудакова Л.В. и др. Способ определения тактики ведения пациентов с увеальной меланомой: Патент № 2019136524. 2019; Singh A.D., Bergman L., Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005;18(1):75– 84. https://doi.org/10.1016/j.ohc.2004.07.002; Damato E.M., Damato B.E. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2384 patients. Ophthalmology 2012;119(8):1582–9. https://doi.org/10.1016/j.ophtha.2012.01.048; Яровой А.А., Малюгин Э.Б., Яровая В.А. и соавт. Тонкоигольная аспирационная биопсия внутриглазных образований. Офтальмохирургия 2020;1:51–56. https://doi.org/10.25276/0235-4160-2020-1-51-56.; Margo C.E. The collaborative ocular melanoma study: an overview. Cancer Control 2004;11(5):304–309. https://doi.org/10.1177/107327480401100504; Яровой А.А. Органосохраняющее и функционально-сберегающее лечение меланомы хориоидеи на основе брахитерапии с рутением-106 и лазерной транспупиллярной термотерапии. Дис. . д-ра мед. наук. М., 2010.; Shah A.A., Bourne T.D., Murali R. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology 2013;45(7):651–6. https://doi.org/10.1097/PAT.0000000000000002; Damato B., Kacperek A., Errington D., Heimann H. Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol 2013;27(3):151–157. https://doi.org/10.1016/j.sjopt.2013.06.014; Саакян С.В., Бородин Ю.И., Ширина Т.В. Оценка эффективности лечения и выживаемости больных увеальной меланомой после лечения медицинским узким протонным пучком. Радиология-практика 2012;6:49–53; Синявский О.А., Трояновский Р.Л., Иванов П.И. и соавт. Пятилетний опыт резекции увеальных меланом после стереотаксической радиохирургии с использованием гамма-ножа. Современные технологии в офтальмологии 2018;1:316–319.; Parker T., Rigney G., Kallos J., et al. Gamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis. Lancet Oncol 2020;21(11):1526–1536. https://doi.org/10.1016/S1470-2045(20)30459-9; Shields C.L., Say E.A. T., Hasanreisoglu M., et al. Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: the 2017 Harry S. Gradle Lecture. Ophthalmology 2017;124(10):1523– 1531. https://doi.org/10.1016/j.ophtha.2017.04.003; Cicinelli M.V., Nicola M.D., Gigliotti C.R., et al. Predictive factors of radio-induced complications in 194 eyes undergoing gamma knife radiosurgery for uveal melanoma. Acta Ophthalmol 2021;99(8):e1458-e1466. https://doi.org/10.1111/aos.14814; Яровая В.А. Прогностическая тонкоигольная аспирационная биопсия увеальной меланомы. Дис. . канд. ме. наук. М., 2020.; Kilic E., Naus N.C., van Gils W., et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci 2005;46(7):2253–7. https://doi.org/10.1167/iovs.04-1460; Singh N., Bergman L., Seregard S., Singh A.D. Uveal melanoma: epidemiologic aspects. Clinical Ophthalmic Oncology. Uveal Tumors 2014:75–88. https://doi.org/10.1007/978-3-642-54255-8_6; Carvajal R.D., Schwartz G.K., Tezel T., et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017;101(1):38–44. https://doi.org/10.1136/bjophthalmol-2016-309034; https://www.malignanttumors.org/jour/article/view/1289

الاتاحة: https://www.malignanttumors.org/jour/article/view/1289
https://doi.org/10.18027/2224-5057-2024-14-1-83-91

المؤلفون: R. K. Minyazeva, G. Y. Battalova, I. V. Sakhautdinova, I. R. Gilyazova

المصدر: Креативная хирургия и онкология, Vol 12, Iss 2, Pp 128-138 (2022)

مصطلحات موضوعية: рак шейки матки, гематогенные метастазы, лимфогенные метастазы, позитронно-эмиссионная томография, компьютерная томография, лучевая терапия, химиотерапия, фтордезоксиглюкоза f18, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.surgonco.ru/jour/article/view/694; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093

URL الوصول: https://doaj.org/article/6a371278eec24d7aabf8ac64435e9b8e

المؤلفون: A. D. Kaprin, V. M. Unguryan, L. O. Petrov, S. A. Ivanov, V. V. Nazarova, Yu. A. Pobedintseva, E. V. Filimonov, E. A. Kruglov

المصدر: Креативная хирургия и онкология, Vol 12, Iss 1, Pp 5-12 (2022)

مصطلحات موضوعية: изолированная химиоперфузия печени, новообразований метастазы, метастазы в печени, увеальная меланома, химиотерапия рака, регионарная перфузия, артериальная перфузия, портальная перфузия, индоцианин зеленый, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.surgonco.ru/jour/article/view/668; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093

URL الوصول: https://doaj.org/article/bcfa5f3985ba4779aa483b4003a8ab36

المؤلفون: S. L. Polyakov, K. V. Paddubny, P. D. Dziameshka, V. V. Sinaika, S. A. Krasny

المصدر: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 20, Iss 5, Pp 494-502 (2022)

مصطلحات موضوعية: пэт/кт, рак предстательной железы, 18f-psma-1007, высокий риск, метастазы, Medicine

وصف الملف: electronic resource

Relation: http://journal-grsmu.by/index.php/ojs/article/view/2898; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109

URL الوصول: https://doaj.org/article/898626c1c9394696a71f1131473ee958